|
Mar 12
|
Zealand Pharma, Roche have 2 best-in-class obesity assets, CEO tells Investing.com
|
|
Mar 12
|
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
|
|
Mar 12
|
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
|
|
Mar 12
|
Roche broadens obesity drug plans with $1.65B Zealand deal
|
|
Mar 12
|
Zealand and Roche strike $5.3bn obesity treatment deal
|
|
Mar 12
|
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
|
|
Feb 20
|
Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology
|
|
Feb 19
|
Q4 2024 Halozyme Therapeutics Inc Earnings Call
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Oct 14
|
Roche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
|
|
Oct 14
|
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
|
|
Oct 14
|
Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
|
|
Oct 14
|
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
|
|
Oct 11
|
Roche wins first-line approval for PI3K inhibitor combo in breast cancer
|
|
Oct 11
|
Roche’s VENTANA CLDN18 assay gains CE mark
|
|
Oct 11
|
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
|
|
Oct 11
|
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
|
|
Oct 10
|
FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
|
|
Oct 10
|
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?
|
|
Oct 10
|
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
|